+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying the safety and effectiveness of a drug called tacabrutideg for people with B-cell malignancies, a type of cancer that affects white blood cells. These cancers include various forms such as chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and others. The study aims to find the best dose of tacabrutideg and evaluate how well it works in shrinking or eliminating these cancers. The study has two parts first, a dose escalation phase where different doses of tacabrutideg are tested to find a recommended dose that is safe and tolerable. Then, an expansion phase enrolls more participants to further assess the safety and effectiveness of the selected dose or doses. Tacabrutideg is given orally. The study includes multiple groups of participants with different types of B-cell malignancies, including some specific cohorts like Japanese participants and those who have not previously received certain kinase inhibitors. Participants will visit clinics regularly over about three years for treatment, health checks, blood tests, tumor imaging, and other assessments. Researchers will monitor side effects, measure cancer response, and collect blood samples to study how the drug behaves in the body. The main outcomes include safety, identifying the best dose, and overall cancer response rates. The study is open label, so both participants and doctors know the treatment given.

Age: 18Years +All GendersPhase 1Phase 2
114 locations
C

Actively Recruiting

Researchers are evaluating nemtabrutinib compared with the investigators choice of ibrutinib or acalabrutinib in adults with untreated chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study aims to determine if nemtabrutinib is not less effective than these treatments in producing an objective response and whether it can improve progression-free survival. This is a Phase 3, randomized trial sponsored by Merck Sharp & Dohme LLC. Participants will be randomly assigned to receive either nemtabrutinib or one of the comparator drugs, ibrutinib or acalabrutinib, all administered orally. Treatment will continue until disease progression, unacceptable side effects, or other reasons for stopping treatment occur. The study compares these treatment options directly to assess their effects on the disease. Throughout the trial, participants will undergo evaluations including tumor response assessments according to established criteria, progression tracking, and safety monitoring for adverse events. These assessments will continue for up to approximately 44 months for the primary response and up to 104 months for progression-free survival and other long-term outcomes. The study involves regular visits and ongoing monitoring to understand how participants respond to the treatments over time.

Age: 18Years +All GendersPhase 3
206 locations
L

Actively Recruiting

Researchers are studying the long-term safety of pirtobrutinib in people who have previously been treated for chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This study welcomes participants who completed the earlier LOXO-BTK-20020 trial to continue receiving the study drug or attend follow-up visits. The study is a Phase 4 treatment trial sponsored by Eli Lilly and Company. Participants will receive pirtobrutinib orally every 4 weeks. There is also a group receiving idelalisib orally. This study is designed as a parallel, non-randomized trial and is expected to last approximately 5 years, allowing continued access to treatment or follow-up for participants from the previous study. During the study, participants will be monitored for treatment-emergent adverse events of grade 3 or higher from the first dose through 30 days after the last dose or start of new anticancer therapy. Researchers will also track overall survival from enrollment in the original study until death from any cause, up to about 93 months. Participants will have regular visits over the study period for safety and health assessments.

Age: 18Years +All GendersPhase 4
50 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of nemtabrutinib in adults with various blood cancers including chronic lymphocytic leukemia CLL, small lymphocytic lymphoma SLL, Richters transformation, marginal zone lymphoma MZL, mantle cell lymphoma MCL, follicular lymphoma FL, and Waldenstrms macroglobulinemia WM. This phase 2 study is sponsored by Merck Sharp & Dohme LLC and involves two parts Dose Escalation and Confirmation Part 1 and Cohort Expansion Part 2, which includes eight disease-specific groups. Participants receive nemtabrutinib tablets orally once daily until their disease progresses or they discontinue the treatment. Part 1 focuses on finding the recommended dose and assessing safety, while Part 2 enrolls participants in specific cohorts based on their disease type and treatment history. Cohorts include various lymphoma and leukemia subtypes, with some requiring prior therapy history and measurable disease criteria. During the study, participants will be monitored regularly for side effects, disease response, and drug levels in the body. Assessments include imaging scans, biopsies, blood tests, and evaluations based on established lymphoma and leukemia criteria. The study measures outcomes such as dose-limiting toxicities, adverse events, treatment discontinuations, and objective response rates over periods ranging from weeks to several years. Participants may stay in the study for up to approximately 5 years, with ongoing monitoring to evaluate the treatments impact and safety.

Age: 18Years +All GendersPhase 2
121 locations